A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

• Status: Recruiting
• Trial end date: 2025-11-03
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Lasmiditan

Criteria

Inclusion Criteria:

• Participants must have completed study H8H-MC-LAHX (NCT03988088) or study H8H-MC-LAHV (NCT number to be determined)

• Participants must weigh at least 15 kilograms (kg)

Exclusion Criteria:

• Participants must not be pregnant or nursing

• Participants must not have any acute, serious, or unstable medical condition

• Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator